Investors Seek GLP-1 Alternatives After Nausea Hurdles
A new wave of weight-loss therapies aims to beat current GLP-1 drugs by reducing side effects and daily dosing. Inves...
Learn the meaning behind the Investor Sentiment Index readings, what drives changes, and how to apply this knowledge to investment decisions.
23,759 articlesA new wave of weight-loss therapies aims to beat current GLP-1 drugs by reducing side effects and daily dosing. Inves...
AI progress rests on more than cool gadgets. This infrastructure stock more sits at the backbone of data centers, clo...
A veteran figure in AI, nicknamed the 'godfather ai,' argues big tech prioritizes short-term profits over the endgame...
A $10,000 investment in Asia’s biggest stocks grew to $15,267 by June 3, 2026, outpacing most U.S. large caps and hig...
As 2026 unfolds, investors face a clear choice between Lilly's growth engine in big markets and Teva's value-forward ...
Markets fall as uncertainty climbs and CEOs adopt a wartime mindset. The shift, described as every wartime now—regard...
Midyear market shifts put Buffett's moat concept under stress as MOAT slips while the broad market climbs. Here’s wha...
A fabless chip ETF is up sharply this year, powered by AI-driven design firms and a deliberate omission of Intel. The...
When markets feel bumpy, dividend stocks uncertain times can anchor a portfolio. Here are two dependable picks—Coca-C...
Discipline beats flashier tactics. A written plan plus automatic investing is the real wealth management secret that ...
The REX AI Equity Premium Income ETF delivers a high headline payout, but its covered-call approach trails the AI ral...
The VanEck PPH ETF faces two key risks in 2026: heavy concentration in Eli Lilly and shifting U.S. drug pricing polic...